About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

NCT02050594·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

With

JSS Medical Research Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Age of 18 years or older on date of first dose of Ipilimumab
Subjects who received at least 1 dose of Ipilimumab for the treatment of unresectable, recurrent or metastatic melanoma in Venezuela

You may not be if

Subjects who received Ipilimumab as part of a clinical trial
Subjects who received Ipilimumab for any indication other than local approval (ie, unresectable or metastatic melanoma)

The record

StatusCompleted

PhaseNo phase

Taking part6

StartedFeb 2014

UpdatedJul 7, 2015

Conditions

Where1

Local Institution
Caracas, Venezuela

Clareo Health | Ipilimumab 12-month Intensive Pharmacovigilance Protocol